Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00102466
Status:
COMPLETED
Last Update Posted:
2020-12-17
First Post:
2005-01-29
Brief Title:
Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is not being conducted in the United States Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug The purpose of this study is to assess the safety and effectiveness of vildagliptin an unapproved drug compared to that of gliclazide in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None